Cidara Therapeutics

Cidara Therapeutics, founded in San Diego, is a biotechnology company dedicated to the discovery, development, and commercialization of novel anti-infectives aimed at treating diseases inadequately addressed by current therapies. Their core mission is to develop targeted immunotherapies that save lives and improve the standard of care for patients with serious diseases. Cidara's primary innovation is the Cloudbreak platform, which creates "single molecule cocktails" by coupling targeted small molecules and peptides to a human antibody fragment (Fc), resulting in drug-Fc conjugate (DFC) immunotherapies.

Notable figures affiliated with Cidara include its experienced leadership team and board members from the biotech and pharmaceutical industries. The company has attracted significant investment from leading venture capital firms and strategic partners. Key achievements include advancing multiple candidates through clinical trials and securing partnerships for further development and commercialization. Cidara's impact lies in its potential to transform treatment paradigms for infectious diseases, offering new hope for patients with limited options.